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Old problems and new developments in the 
fight against the major tropical diseases 
(Joint Symposium with the World Health 
Organisation) 
Novel Approaches to New Drug Targets in 
Protozoan Parasites 
D.E Wirth. Harvard University, Boston, MA, USA 
Parasitic diseases remain a major threat to world health today and 
with the emergence and spread of drug resistance, represent an in- 
creasing threat throughout the world. Yet, drugs for these diseases 
are based on a s m a l l  number of old lead compounds and hence there 
is an urgent need for identification of new targets for drug discovery 
and development. Recent advances in techniques for molecular ge- 
netic analysis and parasitic genome initiatives, including the Malaria 
Genome Sequencing consortium, provide an opportunity to rapidly 
idenhfy and evaluate key metabolic enzymes as potential drug tar- 
gea. These strategies and recent examples of target identification 
will be reviewed. Examples of targets under investigation include 
proteases, enzymes involved in nucleic acid metabolism including di- 
hydrufolate reductase and hypoxanthine phosphoribosyl wansferase, 
lipid metabolism and drug aansport mechanisms. The presentation 
wdl focus on malaria, leishmaniasis and trypanosomiasis. Even with 
the discovery of new drugs, it is necessary to begin to develop strate- 
gies for preventing the rapid emergence of resistance since in recent 
experience, drug resistance is emerging faster than drugs are being 
developed. Multidrug resistance mechanisms and drug efflux and se- 
questration models will be discussed and as will strategies for the 
prevention of resistance. 
Any exciting news in the treatment of malaria 
N.J. White. Faulty .f Tropical Medicine, Mahidol University, Bangkok, 
Tkailand 
Although antimalarial drug resistance in both Pfakiparum and I? uivox 
continues to increase several new treatments have been introduced 
in recent years. There is increasing evidence that the artemisinin 
derivatives are safe, and they have proved the most rapidly acting 
of available antimaianals. In severe malaria the artemisinin deriva- 
tives are at least as effective, and better tolerated than parented 
quinine. The challenge now is to determine which is the best of 
the available compounds. In uncomplicated malaria they retain efi- 
cacy against multi-drug resistant saa ins .  In combination with meflo- 
quine the artemisinin derivatives accelerate the treatment response, 
reduce transmission potential, and increase overall cure rates. Two 
new alternative combinations have proved both effective and re- 
markably well tolerated in the treatment of multi-drug resistance 
uncomplicated malaria. These are artemether-benflumetol and ato- 
vaquone-propanil. With these new drugs the spectre of untreatable 
malaria has receded a little. 
I SlOO 1 Leishmaniasis: A Novel Threat to 
lmmunocompromised Patients, a WHO 
Response 
P Desjeux CTD/TRh:  WHO, Geneva, Suntzerland 
The overlappmg of msceral l e i s h a m  (VL) and AIDS IS mcreasing 
due to the spread of the AIDS pandemc m rural areas and that of 
VL m suburban areas Consequently, cases of co-mfected pahents are 
bemg reported more and more hquently, w t h  important chca l ,  
dIagnoshc, chemotherapeuhc, epidemologd and economc m- 
plications. Leishmania/HIV co-infections are regarded as emerging 
diseases, especially in southern Europe, where 25-70% of adult VL 
cases are related to HIV infection, and 1.59% of AIDS cases suffer 
h m  newly acquired or reactivated VL. In the Mediterranean areas, 
VL is the most frequent opportunistic parasitic mfection. There is 
a clear association between VL and severe immunosuppression. In 
southern Europe there is evidence of a sharp reduction of mean 
survival compared with other AIDS patients. The response to treat- 
ment appears to be worse than in HIV-negative patients. Finally VL 
can remain asymptomatic for years but then evolve into a clinical 
disease in case of immunosuppression. The WHO initiative aims at 
the estabhhment of a surveillance system in order to: - improve the 
coordination and exchange of information between the institutions 
involved, - improve the reliability of the epidemiological data, - im- 
prove the diagnosis, treatment and follow up of co-mfected patients 
and improve the active medical surveillance of the main population 
at risk (intravenous drug users). A network was created of 15 in- 
stitutions h m  10 countries. A standardzed case report form and 
guidelines were elaborated and endorsed by the members of the net- 
work. Finally a central international registxy was set up at WHO to 
centralize, process and a s e  the worldwide information periodi- 
cally. Data concerning 692 retrospective cases are presented here. 
ml The Trials and Tribulations of Developing New 
W E. Gutteridge. Glaxo Welhme Research and Development, 
Beckenham, UK, World Health Organization, Geneua, Switzerland 
Pharmaceutical research and development is scientlfically and tech- 
nically demanding. Hence the process is expensive, time-consuming 
and highly speculative, and successful new products are intrinsically 
expensive. First hand experience of the discovery and development, 
just completed, of the antimalarial fixed combination, atovaquone 
+ propanil, will be reviewed to illustrate just how demanding the 
process can be. Options to deal with the fact that the resulting new 
product is unal€ordable by most patients requiring treatment in dis- 
ease-endemic countries will be described. Finally, current efforts 
within the UNDP/World Bank/WHO Special Programme for Re- 
search and Training in Tropical Diseases (TDR) to form &ance(s) 
with the private pharmaceutical sector to maintain a flow of new 
products for tropical diseases will be summarised. 
Human Antiparasitic Agents 
Short-course treatment of paediatric 
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F] Impact of Pediatric Respiratory Tract Infections 
and Parental Attitudes to Antibiotic Prescribing 
U.B. Schaad. Department ofpediatrics, University o f k e l ,  Basel, 
Switzerland 
Worldwide, in both pediatric and adult patients. respiratory tract in- 
fections are the most common infectious diseases. The majority of 
rcspiratory infections are caused by viruses. For the physicians in- 
volved, the major diagnostic challenge is to diagnose promptly the 
bacterial cases, which can occur as primary or superimposed in- 
fections. Correct diagnosis is important because spec& antibiotic 
therapy is effective against bacterial respiratory tract infections, but 
excessive antibiotic use for respiratory infections induces resistance. 
Prompt and reliable dqnosis is principally based on the clinical 
findings and a few investigations (microbiological, radiological, lab- 
oratory), accordmg to the site of mfection. 
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Recently, telephone interviews were conducted in various Euro- 
pean Countries to determine patients’ attitudes to antibiotic use for 
respiratory tract infections u Int Med Res 1996; 24: 229). Among the 
3610 interviewed, there were about 1200 mothers whose children, 
all less than 12 years of age, had received an antibiotic for a respi- 
ratory infection w i h  the last year. This survey clearly confirmed 
what pediatricians experience every day. Compared with other adults 
in the survey, mothers were the most concerned about respiratory 
tract infections, with 87% overall wanting a doctor to see their child. 
The majority mothers expected an antibiotic to be prescribed, espe- 
c d y  if the chdd had earache, a sore throat, fever, or h c k  catarrh. 
Concerns about giving children antibiotics included the breakdown 
of natural immunity, possible side-effects, addiction and dependency, 
development of resistance, and emotional &dike. Poor compliance 
was adrmtted by approximately 20% of mothers. Reasons for stop- 
ping medxation PremaNely were clitllcal improvement, forgetful- 
ness, dislike of the taste, and wanting to save some antibiotic for 
use on another occasion. Features that interviewees most wanted to 
see improved in an antibiotic were fewer side-effects, improved ef- 
fectiveness, better taste, and more convenient dosage regimen (i.e. 
a reduction in both the number of doses each day and the overall 
duration of treatment). Previous studies have shown that decreasing 
the complexity of an antibiotic regimen (e.g. once-daily dosing and 
3- to 5-day duration) does improve patient compliance. 
I S103 I In witm Sensitivity of Macrolides in Europe: 
H.E. Akalin. @zer-Turkqs Istanbul, Turkey 
Macrolide antibiotics are usually used in the treatment of commu- 
nity-acquired respiratory tract infections. Because their use is gener- 
ally empiric, bacterial susceptibility to these agents must be closely 
followed to ensure appropriate use. Streptocorn pneumoniae, Strep- 
tocoms j i yopes ,  Haemophilus intuenzae, and Moraxella catarrhalis are 
the most common bacterial pathogens responsible for respiratory 
tract infections. The availability of advanced-generation macrolides 
has influenced the practice of physicians in the treatment of these 
infections. 
The ARTEMIS project is an international antimicrobial suscep- 
tibfity surveillance study  of various bacterial pathogens. Forty-five 
countries worldwide are induded in the study 14 of these countries 
are European. Results of Phase I of the project will be presented. 
A total of 1559 respiratory pathogens from six European countries 
were evaluated. Susceptibilities of these pathogens to azithromycin, 
clarithromycin, roxithromycin, erythromycin, and ampicdin (when 
indicated) were tested. E-test was used as standarcbzed antibiotic sus- 
ceptibility testing, except for H. inauenzae. MIC90s of azithromycin, 
clarithromycin, and roxithromycin, respectively, for various respira- 
tory pathogens were as follows: S. pneumoniae 1 mg/l, 1 mg/l and, 
1 mgfl; H. injwnzae 2 mgfl, 16 mgfl and 16 mg/l M .  catarrhalis 
0.25 mgfl, 0.25 mg/l, and 1.0 mgA. There was no major resistance 
in S. pyogenes against these antimicrobials. The ARTEMIS project is 
s t i l l  ongoing. Further analysis of the data will enable identification of 
changes in resistance patterns of these and other pathogens that are 
included in the project. 
Results of the ARTEMIS Study 
1 S104 I Otitis Media: A Case for Single-Dose Therapy? 
A. Arguedas. Pediafric Infertious Diseases, Medicine 1 Department, 
National Children’s Hospital, San Jose, Costa Rim 
Acute otitis media (AOM) is one of the most common mfectious 
diseases of childhood, with bacterial pathogens isolated f b m  middle 
ear fluid in about two-thirds of patients. Selection of an antiobiotic 
for the treatment should be based on antimicrobial spectrum, phar- 
macokinetic properties, safety, and cost. Although, at present, 10 
days is considered the standard duration of therapy, some problems, 
such as poor compliance and drug-related side-effects, suggest the 
need for shorter therapeutic regimens. Five-day oral and single-dose 
intramuscular cephalosporins have produced promising results; how- 
ever, the lack of an oral preparation in the case of ceftriione and 
the possibility of selection of resistance kmit the use cephalosporins 
to more invasive &eases and preclude their routine use for AOM. 
Azithromycin is an azalide antimicrobial with good in viho activ- 
ity against middle ear pathogens, high middle ear penetration, and a 
prolonged half-life (35-56 h). When tested in patients with AOM 
as a 3-day regimen compared with standard agents, azithromycin 
has a n  excellent c h c a l  and bacteriological efficacy, and a good 
safety profile. A double-blind h c a l  trial comparing single-dose 
oral azithromycin, 3-day azithromycin, and single-dose intramus- 
cular cefaiaxone in pedutric patients with bacteriologically proven 
AOM is ongoing in Costa Rica and is s t i l l  blinded; however, of 
139 patients included, 128 have completed the trial. Middle ear cul- 
tures have been positive in 73% of the patients, the most common 
pathogens being Streptococm pneumoniae (46%) and Haemophilus in- 
juenzae (25%). The c h c a l  response to therapy has been classed 
as satisfactory (cure or improvement) in 115 (93.4%) patients, and 
presumed eradication has been recorded in 94.4% of the patients. 
Rates of persistence of middle ear efision have been comparable to 
standard agents. Adverse events, mainly gastrointestinal, have been 
observed in three patients (2.4%). These data suggest that larger 
chical t r d  with single-dose azithromycin in pediatric patients are 
warranted. 
I S105 I Lower Respiratory Tract Infections: Clinical Use 
of Azithromycin 
P. Marchisio. Pediatric Department 4, University cf Milan, Milan, Italy 
Acute lower respiratory infections include a variety of clinical con&- 
tions (e.g. pneumonia, broncholitis, and acute bronchtis). Pneumo- 
nia is of particular importance both in developing countries, where 
it contributes considerably to childhood mortality, and developed 
countries, where its social impact is st i l l  sigdicant. Prospective stud- 
ies indicate that many episodes of pneumonia are associated with 
viral infection. However, the h t a t ions  of currently available di- 
agnostic techmques in routine c h c a l  practice mean that children 
with pneumonia are usually treated with antimicrobds, especially 
p-lactams. This choice of antibiotic is often unsatisfactory because 
of the increasing incidence of bacterial resistance, hypersensitiv- 
ity, and their lack of activity against atypical respiratory pathogens. 
As a result, estabhhed and newer macrolides have been increas- 
ingly used as alternative therapies. Among the new compounds, 
adthromycin, which belongs to azalide class, has a high bioavail- 
ability and prolonged halt-life, achieves sustained and elevated tissue 
levels, and has a broad antibacterial spectrum of activity that includes 
Gram-positive, Gram-negative, and intracellular microorganisms. 
In the past few years, azithromycin has been compared to 
first-choice antimicrobial drugs in the treatment of commu- 
nity-acquired pneumonia. In particular, azithromycin 10 mg/kg 
given once daily for 3 days has been demonstrated to be as effec- 
tive and safe as a standard 10-day course of erythromycin (principi, 
et al. Eur J Clin Res 1993; 4: 127. De Mol, et al. 3rd ICMAS, 
1996), or amoxicillin/clavulanic acid (Treadway, et al. 3rd ICMAS, 
1996; Rodriguez, et al. 3rd ICMAS, 1996). The good tolerability 
of azithromycin, combined with its shorter and simpler dosing reg- 
imen, may substantially increase comphce ,  which is of particular 
&cal importance when treating children. 
